Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

366/433 Matches for
“Hepatology”

“Hepatology” Clear all
  1. Noninvasive assessment of portal hypertension in patients with cirrhosis.

    Thabut D et al. · Hepatology · 2011 Match 100

    Severe portal hypertension is responsible for complications and death. Although measurement of…

    FibroTest Alcohol HBV HCV +3

  2. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 100

    ActiTest FibroTest HBV

  3. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 100

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  4. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 100

    BACKGROUND: Biochemical marker combinations, including alpha2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl…

    ActiTest FibroTest Alcohol HBV +3

  5. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 100

    ActiTest FibroTest HCV

  6. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 100

    FibroTest Alcohol HBV HCV +3

  7. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Match 100

    ### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…

    FibroTest HCV

  8. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 100

    SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and…

    ActiTest FibroTest HCV

  9. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 99

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  10. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 99

    ### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…

    FibroTest Metabolic

  11. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 99

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  12. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 99

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  13. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 99

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  14. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

    Castéra L et al. · J Hepatol · 2009 Match 99

    ### Background/Aims To assess prospectively the accuracy of transient elastography (TE, FibroScan…

    FibroTest HCV

  15. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 99

    FibroTest Alcohol

  16. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 98

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  17. Diagnostic value of FibroTest with normal serum aminotransferases.

    Poynard T et al. · Hepatology · 2006 Match 98

    FibroTest HCV

  18. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 98

    ActiTest FibroTest HBV

  19. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 98

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  20. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 98

    The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…

    FibroTest HBV HCV HIV

  21. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 98

    ActiTest FibroTest HCV

  22. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012 Match 98

    ### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…

    FibroTest HCV

  23. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010 Match 97

    …study was conducted in the Hepatology departments of 23 French university hospitals…

    FibroTest HBV HCV HIV

  24. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.

    Halfon P et al. · Comp Hepatol · 2002 Match 97

    BACKGROUND: Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are…

    ActiTest FibroTest Alcohol HCV

  25. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

    Sebastiani G et al. · J Hepatol · 2006 Match 97

    ### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…

    FibroTest HCV

  26. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Match 97

    Liver fibrosis and activity indexes were validated in patients infected by hepatitis…

    ActiTest FibroTest HCV

  27. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

    Leroy V et al. · J Hepatol · 2007 Match 97

    ### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…

    FibroTest HCV

  28. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 97

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  29. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 97

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  30. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Match 97

    ### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…

    ActiTest FibroTest HBV

  31. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

    Bedossa P et al. · Hepatology · 1996 Match 96

    Histological activity reflects the global assessment of basic necroinflammatory lesions and is…

    HCV

  32. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 96

    ### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…

    FibroTest HCV

  33. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.

    Cacoub P et al. · J Hepatol · 2008 Match 96

    ### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…

    FibroTest HCV HIV

  34. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.

    Carlson JJ et al. · J Gastroenterol Hepatol · 2009 Match 96

    ### Background And Aim To assess the clinical and economic outcomes of non…

    FibroTest

  35. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 96

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  36. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 96

    FibroTest SteatoTest Metabolic

  37. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 96

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  38. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 95

    Although most hepatitis C virus (HCV) infections are acquired by injection drug…

    FibroTest

  39. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

    Boursier J et al. · Hepatology · 2012 Match 95

    ### Unlabelled The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm…

    FibroTest HCV

  40. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 95

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  41. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 95

    ### Background & Aims The aim of this study was to determine the diagnostic…

    FibroTest Alcohol

  42. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 95

    ### Background Chronic HCV is one of the major causes of morbidity and…

    FibroTest HCV

  43. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 95

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  44. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 95

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  45. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 94

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  46. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 94

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  47. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 94

    ### Background & Aims Although methotrexate (MTX) is used in the effective treatment of…

    FibroTest Other

  48. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

    Halfon P et al. · J Hepatol · 2007 Match 94

    ### Background/Aims We evaluated the test performance profile (TPP) of blood tests…

    FibroTest HCV

  49. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.

    Zarski JP et al. · Liver Int · 2010 Match 94

    ### Background The efficacy of a maintenance therapy in non-responder patients with…

    ActiTest FibroTest HCV

  50. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 94

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  51. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 94

    ### Background & Aims The first aim was to extend the validation of FibroTest…

    ActiTest FibroTest HBV

  52. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 94

    ### Background/Aims The aim was to identify a panel of biomarkers (AshTest…

    AshTest Alcohol

  53. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.

    Calès P et al. · J Hepatol · 2010 Match 93

    ### Background & Aims We compared 5 non-specific and 2 specific blood tests…

    FibroTest HCV HIV

  54. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 93

    ### Aims And Methods Several serum biomarkers such as FibroTest, aspartate transaminase-platelet…

    FibroTest Alcohol HBV HCV +3

  55. A novel panel of blood markers to assess the degree of liver fibrosis.

    Calès P et al. · Hepatology · 2005 Match 93

    The objective was to develop new blood tests to characterize different fibrosis…

    FibroTest Alcohol HBV HCV

  56. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 93

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  57. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012 Match 93

    ### Background & Aims Most liver transplant centres have discontinued the practice of protocol…

    ActiTest FibroTest Alcohol HBV +4

  58. The use of enzyme results for liver fibrosis evaluation neccessitates standardization.

    Myara A et al. · Hepatology · 2008 Match 93

    FibroTest HBV HCV HIV

  59. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 93

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  60. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.

    Lewin M et al. · Hepatology · 2007 Match 92

    ### Unlabelled Liver biopsy is the gold standard for assessing fibrosis but has…

    FibroTest HCV

  61. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

    Patel K et al. · J Viral Hepat · 2009 Match 92

    Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…

    FibroTest HCV

  62. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 92

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  63. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.

    de Lédinghen V et al. · J Pediatr Gastroenterol Nutr · 2007 Match 92

    ### Objective Transient elastography (FibroScan) is a novel, noninvasive, rapid bedside method to…

    FibroTest HBV HCV Other

  64. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009 Match 92

    ### Background/Aims The aim of this study was to compare the performance…

    FibroTest HBV HIV

  65. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 92

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  66. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

    Colletta C et al. · Hepatology · 2005 Match 92

    The course of hepatitis C virus (HCV) infection carriers with normal/near…

    FibroTest HCV

  67. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 91

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  68. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 91

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  69. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 91

    ### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…

    FibroTest Alcohol

  70. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.

    Dai CY et al. · J Hepatol · 2010 Match 91

    ### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…

    FibroTest HBV HCV

  71. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.

    Boursier J et al. · Eur J Gastroenterol Hepatol · 2009 Match 91

    ### Objective Blood tests are usually designed to identify significant fibrosis. We evaluated…

    FibroTest HCV

  72. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 91

    ### Background & Aims Real-time shear wave elastography (SWE) is a new two…

    FibroTest Alcohol HBV HCV +3

  73. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

    Castéra L et al. · Gastroenterology · 2005 Match 91

    ### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…

    FibroTest HCV

  74. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 91

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  75. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.

    Liu S et al. · PLoS One · 2011 Match 90

    ### Background And Aims Chronic hepatitis C (HCV) is a liver disease affecting…

    FibroTest HCV

  76. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.

    Moussalli J et al. · Gastroenterol Res Pract · 2010 Match 90

    Barriers to management of HCV in injection drug users are related to…

    ActiTest FibroTest HCV

  77. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 90

    ### Background & Aims There is controversy about the performance of noninvasive tests such…

    FibroTest Alcohol HBV HCV +3

  78. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 90

    ActiTest AshTest FibroTest NashTest +6

  79. Noninvasive prediction of fibrosis in patients with chronic hepatitis C.

    Thabut D et al. · Hepatology · 2003 Match 90

    FibroTest HCV

  80. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009 Match 90

    ### Unlabelled The staging of liver fibrosis is pivotal for defining the prognosis…

    FibroTest HCV

  81. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.

    Pokorska-Śpiewak M et al. · Clin Exp Hepatol · 2017 Match 90

    ### Aim Of The Study Was to evaluate liver disease severity in children…

    ActiTest FibroTest HBV HCV

  82. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 89

    ### Background Liver stiffness and non-invasive tests predict overall survival in chronic…

    FibroTest HBV

  83. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 89

    ### Background And Aims Despite the high prevalence of chronic hepatitis B (CHB…

    FibroTest HBV

  84. Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.

    Kucharska M et al. · Adv Clin Exp Med · 2015 Match 89

    Haemophilia is an entity, wherein the HCV infection rate is greater than…

    FibroTest HCV

  85. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 89

    ### Background The prediction of fibrosis is an essential part of the assessment…

    FibroTest HCV

  86. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 89

    The aim of this study was to evaluate the diagnostic values of…

    FibroTest Alcohol

  87. Fibroscan and FibroTest/FibroMax to assess liver fibrosis/cirrhosis in patients with chronic HBV and HCV infection in Georgia.

    Dolmazashvili E et al. · Georgian Med News · 2008 Match 89

    …These patients were investigated at the Georgian-French Joint Hepatology Clinic "Hepa…

    ActiTest AshTest FibroTest NashTest +3

  88. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.

    Hermeziu B et al. · Gastroenterol Clin Biol · 2010 Match 89

    FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…

    ActiTest FibroTest HCV

  89. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 88

    ### Background This prospective, monocentric study was designed to assess the efficacy of…

    FibroTest Alcohol HBV HCV +2

  90. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 88

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  91. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 88

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  92. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 88

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  93. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 88

    ### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…

    FibroTest HBV HCV Other

  94. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.

    Sebastiani G et al. · J Viral Hepat · 2008 Match 88

    In chronic hepatitis C, biopsy is the gold standard for assessment of…

    FibroTest HCV

  95. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

    Myers RP et al. · AIDS · 2003 Match 88

    ### Objective Liver biopsy, the gold standard for assessing hepatitis C virus (HCV…

    FibroTest HCV HIV

  96. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 88

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  97. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.

    Bonnard P et al. · J Viral Hepat · 2015 Match 87

    In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…

    FibroTest HCV

  98. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?

    Gentile I et al. · Infez Med · 2014 Match 87

    It is estimated that hepatitis C virus (HCV) infects chronically about 160…

    FibroTest HCV

  99. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

    Boursier J et al. · Aliment Pharmacol Ther · 2014 Match 87

    ### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…

    FibroTest HCV

  100. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 87

    ### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…

    FibroTest HCV

  101. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 87

    ActiTest AshTest FibroTest NashTest +7

  102. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 87

    ActiTest FibroTest Alcohol HBV +3

  103. Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C.

    Maor Y et al. · Haemophilia · 2010 Match 87

    Non-invasive modalities to estimate fibrosis stage are desirable in hepatitis C…

    FibroTest HCV

  104. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 86

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  105. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 86

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  106. Changes of non-invasive markers and FibroScan values during HCV treatment.

    Vergniol J et al. · J Viral Hepat · 2009 Match 86

    The recent advent of non-invasive methods for assessment of fibrosis allows…

    FibroTest HCV

  107. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 86

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  108. Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?

    Sebastiani G et al. · Hepatology · 2012 Match 86

    FibroTest HCV

  109. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Match 86

    ### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…

    FibroTest HBV HCV

  110. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 86

    FibroTest HBV

  111. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.

    Park MS et al. · Liver Int · 2015 Match 85

    ### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…

    FibroTest HBV

  112. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.

    Sène D et al. · Clin Biochem · 2006 Match 85

    ### Objective And Methods We assessed the reliability of non-invasive biological scoring…

    ActiTest FibroTest HCV

  113. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 85

    Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…

    FibroTest Alcohol

  114. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.

    Myers RP et al. · Am J Gastroenterol · 2002 Match 85

    ### Objectives Liver fibrosis in chronic hepatitis C is related to sex, age…

    FibroTest HCV

  115. Combination of fibrosis tests: sequential or synchronous?

    Boursier J et al. · Hepatology · 2009 Match 85

    FibroTest HCV

  116. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2012 Match 85

    ### Background Preliminary data suggest that performance of non-invasive markers for liver…

    FibroTest HCV

  117. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.

    Mallet V et al. · Aliment Pharmacol Ther · 2009 Match 85

    ### Background The Fib-4 index is a simple and inexpensive biomarker to…

    FibroTest HBV

  118. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.

    Vallet-Pichard A et al. · Hepatology · 2006 Match 85

    FibroTest HCV

  119. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 84

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  120. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 84

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  121. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.

    Calès P et al. · Liver Int · 2008 Match 84

    ### Background The reliable diagnosis rate of diagnostic tests is provided by their…

    FibroTest HCV

  122. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.

    Köksal İ et al. · Turk J Gastroenterol · 2018 Match 84

    ### Background/Aims The hepatitis C virus (HCV) infection is important cause of…

    FibroTest HCV

  123. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 84

    Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…

    ActiTest FibroTest HCV

  124. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 84

    ### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…

    FibroTest HCV

  125. Clinical applicability of non-invasive markers for liver fibrosis in chronic hepatitis C (Letter)

    Match 84

    FibroTest HCV

  126. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 83

    ### Aim To assess the performance of several non-invasive markers and of…

    FibroTest HBV

  127. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 83

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  128. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 83

    ### Background And Aims Blood tests and liver stiffness evaluation (LSE) by ultrasonographic…

    FibroTest Alcohol HBV HCV +2

  129. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 83

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  130. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 83

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  131. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 83

    FibroTest Metabolic

  132. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 83

    ### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…

    SteatoTest Metabolic

  133. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 82

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  134. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 82

    ### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…

    SteatoTest Metabolic

  135. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008 Match 82

    FibroTest Alcohol HBV HCV +1

  136. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.

    Bonnard P et al. · Am J Trop Med Hyg · 2010 Match 82

    Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…

    FibroTest HBV

  137. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 82

    ### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…

    FibroTest SteatoTest Other

  138. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

    Corradi F et al. · Dig Liver Dis · 2009 Match 82

    ### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…

    FibroTest HCV

  139. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Match 82

    ### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…

    FibroTest HBV HCV

  140. Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B.

    Cheng J et al. · PLoS One · 2015 Match 82

    ### Background And Aims Noninvasive models have been developed for fibrosis assessment in…

    FibroTest HBV

  141. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.

    Zeremski M et al. · BMC Gastroenterol · 2014 Match 81

    ### Background Noninvasive markers of liver fibrosis have not been extensively studied in…

    ActiTest FibroTest HBV

  142. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 81

    ### Background And Aims Hepatobiliary disorders, associated either with extraintestinal manifestations or with…

    FibroTest Other

  143. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Match 81

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  144. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 81

    ### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…

    NashTest SteatoTest Metabolic

  145. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 81

    ### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…

    FibroTest

  146. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 81

    ### Background And Aims We aimed to determine the best algorithms for the…

    FibroTest HCV

  147. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 81

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  148. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 80

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  149. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 80

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  150. Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?

    Ofei SY et al. · Int J Cardiol · 2015 Match 80

    FibroTest Other

  151. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 80

    ### Background And Aims The PGAA index was one of the first composite…

    FibroTest Alcohol

  152. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.

    Poynard T et al. · J Viral Hepat · 2002 Match 80

    A liver fibrosis index was recently prospectively validated in a cross-sectional…

    FibroTest HCV

  153. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 80

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  154. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Match 80

    ### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…

    Elasto-FibroTest FibroTest HCV

  155. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 79

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  156. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 79

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  157. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 79

    ### Aim To compare noninvasive methods presently used for steatosis detection and quantification…

    SteatoTest Metabolic

  158. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 79

    ### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…

    FibroTest HBV

  159. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 79

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  160. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 79

    ### Background And Aims We aimed to determine the best algorithms for the…

    FibroTest HCV

  161. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 79

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  162. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 79

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  163. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 78

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  164. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 78

    Chronic hepatitis B virus (HBV) infection is a major cause of liver…

    FibroTest HBV

  165. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 78

    ### Objective There is a controversy about the performance of blood tests for…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  166. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 78

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  167. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.

    Alric L et al. · Transpl Int · 2009 Match 78

    To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…

    FibroTest HBV HCV

  168. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.

    Halfon P et al. · Antivir Ther · 2009 Match 78

    ### Background Non-invasive liver fibrosis scores have been proposed as alternatives to…

    FibroTest HCV HIV

  169. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Match 78

    ### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…

    ActiTest FibroTest Alcohol HBV +1

  170. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 77

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  171. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.

    Halfon P et al. · Am J Gastroenterol · 2006 Match 77

    ### Objectives Fibrotest (FT) and Actitest (AT) are biochemical markers of fibrosis and…

    ActiTest FibroTest HCV

  172. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 77

    ### Background And Aims Diagnostic values of FibroTest (FT) for hepatic fibrosis have…

    FibroTest HBV

  173. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 77

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver…

    FibroTest Alcohol HBV HCV +1

  174. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 77

    ### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…

    ActiTest FibroTest HCV

  175. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 77

    ### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…

    FibroTest Alcohol

  176. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 77

    ### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…

    FibroTest HCV

  177. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 76

    ### Background Noninvasive tests are crucial for the management and follow-up of…

    ActiTest FibroTest AIH

  178. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 76

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  179. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 76

    ### Background In recent years noninvasive methods have been evaluated for the assessment…

    FibroTest SteatoTest Other

  180. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

    Tran A et al. · Clin Res Hepatol Gastroenterol · 2022 Match 76

    Hepatitis C virus (HCV) infection is a major cause of chronic liver…

    FibroTest HCV

  181. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.

    Chen J et al. · J Clin Lab Anal · 2013 Match 76

    ### Background Noninvasive laboratory tests have been widely used in the diagnosis of…

    FibroTest HBV

  182. Toward non-invasive assessment strategies in autoimmune hepatitis.

    Jerez Diaz D et al. · World J Hepatol · 2025 Match 76

    In this article, we comment on the article by Peta _et al…

    ActiTest FibroTest AIH

  183. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.

    Boursier J et al. · Am J Gastroenterol · 2011 Match 76

    ### Objectives Precise evaluation of the level of liver fibrosis is recommended in…

    FibroTest HCV

  184. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 75

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  185. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 75

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  186. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.

    Uyar C et al. · Indian J Pathol Microbiol · 2010 Match 75

    ### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…

    ActiTest FibroTest HBV HCV

  187. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 75

    ### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…

    FibroTest SteatoTest Alcohol

  188. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 75

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  189. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 75

    Alcohol is one of the main factors of liver damage. The evaluation…

    FibroTest Alcohol

  190. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Match 75

    ### Background & Objectives One of the multiple factors contributing to virological response in…

    ActiTest FibroTest SteatoTest HCV

  191. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 75

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  192. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 74

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  193. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 74

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  194. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 74

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  195. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023 Match 74

    FibroTest Metabolic

  196. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.

    Le Calvez S et al. · Hepatology · 2004 Match 74

    FibroTest HCV

  197. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 74

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  198. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 74

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  199. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Match 73

    FibroTest HCV

  200. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

    Asselah T et al. · Liver Int · 2018 Match 73

    ### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…

    FibroTest HCV

  201. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 73

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  202. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 73

    ### Background Few data are available on chronic hepatitis C (CHC) in elderly…

    FibroTest HCV

  203. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.

    Castera L et al. · Hepatology · 2006 Match 73

    FibroTest HCV

  204. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 73

    FibroTest Other

  205. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?

    Maor Y et al. · Haemophilia · 2006 Match 73

    Liver biopsy remains the gold standard for the evaluation of fibrosis despite…

    FibroTest HCV

  206. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.

    Shaheen AA et al. · HIV Clin Trials · 2008 Match 72

    ### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…

    FibroTest HCV HIV

  207. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

    Yakoob R et al. · Ann Gastroenterol · 2015 Match 72

    ### Background The aim of this study was to compare noninvasive biomarkers, FibroTest…

    ActiTest FibroTest HCV

  208. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.

    Sökücü S et al. · Scand J Infect Dis · 2010 Match 72

    The aim of this study was to investigate whether the non-invasive…

    ActiTest FibroTest HBV

  209. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 72

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  210. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

    Patel K et al. · Aliment Pharmacol Ther · 2016 Match 72

    ### Background Assessment of fibrosis progression in chronic liver disease relies upon non…

  211. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 72

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  212. Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

    White DL et al. · Dig Dis Sci · 2012 Match 72

    ### Aim We evaluated the association between two medications that alter bioavailable androgen…

    ActiTest FibroTest HCV

  213. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 72

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…

    FibroTest SteatoTest Metabolic

  214. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

    Maor Y et al. · Haemophilia · 2007 Match 71

    Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…

    FibroTest HCV

  215. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.

    Usluer G et al. · Eur J Clin Microbiol Infect Dis · 2012 Match 71

    The aim of this study was to compare the results of nine…

    FibroTest HCV

  216. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 71

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…

    FibroTest

  217. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 71

    FibroTest HCV

  218. Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.

    Mossong J et al. · Bull Soc Sci Med Grand Duche Luxemb · 2011 Match 71

    ### Objective The aim of our study was to assess the diagnostic performance…

    FibroTest HCV

  219. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 71

    The aim was to assess the utility of FibroTest-ActiTest (FT-AT…

    ActiTest FibroTest HBV

  220. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 71

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  221. Implementing non-invasive markers for liver fibrosis in clinical practice.

    Sebastiani G et al. · J Hepatol · 2008 Match 70

    FibroTest HCV

  222. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 70

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  223. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Match 70

    ### Background We previously reported on serum N-glycans as markers for the…

    FibroTest HBV

  224. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Match 70

    ### Background Due to common routes of transmission, HIV and HBV are frequently…

    FibroTest HBV HIV

  225. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication

    Imbert-Bismut F et al. · Lancet · 2001 Match 70

    ### Background Liver biopsy is thought mandatory for management of patients with hepatitis…

    FibroTest HCV

  226. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.

    Bosselut N et al. · Clin Chim Acta · 2013 Match 70

    ### Background Noninvasive methods for liver fibrosis evaluation in chronic liver diseases have…

    FibroTest HCV

  227. Analytical variability of the Fibrotest proteins.

    Rosenthal-Allieri MA et al. · Clin Biochem · 2005 Match 70

    ### Objectives The analytical variability of the Fibrotest (FT) parameters raises the issue…

    FibroTest HCV

  228. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.

    Callewaert N et al. · Nat Med · 2004 Match 69

    We applied our 'clinical glycomics' technology, based on DNA sequencer/fragment analyzers…

    FibroTest Alcohol Other

  229. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

    Fontanges T et al. · Gastroenterol Clin Biol · 2008 Match 69

    ### Introduction The purpose of this clinical trial was to determine in routine…

    ActiTest FibroTest HCV

  230. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 69

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  231. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 69

    ### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…

    ActiTest FibroTest HCV

  232. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 69

    A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…

    FibroTest HBV

  233. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

    Castera L et al. · J Hepatol · 2007 Match 69

    FibroTest HCV

  234. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 69

    FibroTest Metabolic

  235. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

    Boyd A et al. · J Int AIDS Soc · 2017 Match 69

    ### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…

    FibroTest HBV HIV

  236. Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    Thabut D et al. · Aliment Pharmacol Ther · 2007 Match 68

    ### Background The best technique to estimate portal hypertension (PHT) is to measure…

    FibroTest Alcohol HBV HCV +2

  237. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.

    Miailhes P et al. · J Viral Hepat · 2011 Match 68

    Transient elastography (TE) is a noninvasive technique to evaluate liver fibrosis. We…

    FibroTest HBV HIV

  238. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.

    Leroy V et al. · J Hepatol · 2014 Match 68

    ### Background & Aims Fibrosis blood tests have been validated in chronic hepatitis C…

    FibroTest HBV HCV

  239. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.

    Boursier J et al. · BMC Gastroenterol · 2011 Match 68

    ### Background Non-invasive tests have been constructed and evaluated mainly for binary…

    FibroTest HCV

  240. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 68

    ### Context Recently, it has been shown that an allele in the adiponutrin…

    FibroTest Metabolic

  241. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012 Match 68

    ### Background Acoustic radiation force impulse (ARFI) imaging is a new non-invasive…

    FibroTest Alcohol HBV HCV +3

  242. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

    Imbert-Bismut F et al. · Clin Chem Lab Med · 2004 Match 68

    Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…

    ActiTest FibroTest HCV

  243. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.

    Thabut D et al. · Liver Int · 2006 Match 67

    ### Background And Aims Primary prevention of variceal bleeding with beta-blockers improves…

    FibroTest Alcohol HBV HCV

  244. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 67

    ### Purpose To compare the diagnostic performance of acoustic radiation force impulse (ARFI…

    FibroTest Alcohol HBV HCV +2

  245. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Match 67

    ### Objective Studies have shown that patients with failing Fontan circulation may develop…

    ActiTest FibroTest Other

  246. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.

    Munteanu M et al. · Clin Biochem · 2008 Match 67

    FibroTest Alcohol HBV HCV +1

  247. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014 Match 67

    FibroTest HBV

  248. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Match 67

    FibroTest Alcohol HBV HCV +1

  249. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 67

    FibroTest HCV

  250. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.

    Goldschmidt I et al. · J Pediatr Gastroenterol Nutr · 2014 Match 66

    ### Background The development of esophageal varices is a late complication of chronic…

    FibroTest Other

  251. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 66

    ActiTest FibroTest NashTest-2 Metabolic

  252. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.

    Bourliere M et al. · Aliment Pharmacol Ther · 2008 Match 66

    ### Background Non-invasive liver fibrosis scores such as Hepascore (HS) have been…

    FibroTest HCV

  253. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 66

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  254. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014 Match 66

    Liver biopsy, which was traditionally considered to be the gold standard for…

    FibroTest HBV HCV

  255. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

    Vallet-Pichard A et al. · Hepatology · 2007 Match 66

    ### Unlabelled To optimize the management of patients with chronic hepatitis C virus…

    FibroTest HCV

  256. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 66

    ### Background Direct antiviral agents (DAA) showed very good results in terms of…

    FibroTest HCV

  257. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 66

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  258. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 65

    ### Background No blood test has been shown to be effective in the…

    LCR1 LCR2 Alcohol HBV +4

  259. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 65

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  260. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 65

    ### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…

    AshTest Alcohol

  261. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 65

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  262. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 65

    ### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…

    FibroTest HIV

  263. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 65

    ### Background Urea cycle disorders (UCDs) are among the most common inborn errors…

    ActiTest FibroTest Other

  264. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 65

    …who were referred to our hepatology clinic for assessment of fitness for…

    HCV

  265. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014 Match 64

    FibroTest HBV

  266. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 64

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  267. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 64

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…

    FibroTest Other

  268. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 64

    ### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…

    FibroTest

  269. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Match 64

    Patients infected with hepatitis C virus (HCV) have differing levels of liver…

    FibroTest HCV

  270. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 64

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  271. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 64

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  272. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 63

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  273. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 63

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  274. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 63

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  275. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 63

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  276. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

    d'Arondel C et al. · J Viral Hepat · 2006 Match 63

    In therapy with standard interferon and ribavirin, five independent risk factors (RF…

    ActiTest FibroTest HCV

  277. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 63

    As of 2016, there is no evidence-based pathway to stratify the…

    FibroTest Other

  278. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 63

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  279. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 63

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  280. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 62

    ### Background Previous research has shown variation in the effects of patient factors…

    FibroTest HCV

  281. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 62

    ### Background Although the FibroTest has been validated as a biomarker to determine…

    FibroTest Alcohol HBV HCV +1

  282. Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

    Calès P et al. · Clin Biochem · 2010 Match 62

    ### Objectives To optimize the performance and feasibility of fibrosis blood tests and…

    FibroTest HCV

  283. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 62

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  284. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 62

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  285. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 62

    ### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…

    ActiTest FibroTest HCV

  286. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 62

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver…

    FibroTest HBV HIV

  287. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 61

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  288. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 61

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  289. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 61

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  290. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 61

    Chronic hepatitis B (CHB) infection is a major public health problem associated…

    FibroTest HBV

  291. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.

    Calès P et al. · Gastroenterol Clin Biol · 2008 Match 61

    ### Objective To evaluate the rates of reliable diagnosis of cirrhosis by two…

    FibroTest HCV

  292. Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.

    Munteanu M et al. · Scand J Infect Dis · 2011 Match 61

    ActiTest FibroTest HCV

  293. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.

    Rossi E et al. · Clin Chem · 2003 Match 61

    ### Background Determining the stage of fibrosis by liver biopsy is important in…

    FibroTest HCV

  294. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 60

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  295. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 60

    FibroTest Alcohol HBV HCV +1

  296. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.

    Rosenthal-Allieri MA et al. · Gastroenterol Clin Biol · 2007 Match 60

    ### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…

    ActiTest FibroTest HCV

  297. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 60

    ### Background There is a clear need for better biomarkers of drug-induced…

    ActiTest FibroTest Other

  298. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 60

    ### Purpose Transient elastography (FibroScan, [TE]) and serum fibrosis markers such as the…

    FibroTest Alcohol HBV HCV +2

  299. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007 Match 60

    ### Background The area under the receiver operating characteristic (ROC) curve is widely…

    FibroTest HCV

  300. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 60

    Acute hepatitis C virus infection remains a major health concern in human…

    FibroTest HCV HIV

  301. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

    Akuta N et al. · J Gastroenterol · 2018 Match 60

    ### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…

    FibroTest HCV

  302. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 59

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  303. Non-invasive diagnosis and follow-up of portal hypertension.

    Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022 Match 59

    Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis…

    FibroTest Alcohol HBV HCV +1

  304. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 59

    …While transient elastography (TE) is an established elastography method in hepatology centers…

    FibroTest Other

  305. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 59

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  306. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Match 59

    ### Aim To assess the usefulness of FibroTest to forecast scores by constructing…

    FibroTest HCV

  307. Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.

    · Geriatr Gerontol Int · 2015 Match 59

    FibroTest HCV

  308. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.

    Park MS et al. · PLoS One · 2013 Match 59

    ### Background And Aims The FibroTest (FT) demonstrated excellent diagnostic performance in the…

    FibroTest HBV

  309. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 58

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  310. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 58

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

  311. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 58

    ### Background And Aims Real-time shear wave elastography (2D-SWE) is a…

    ActiTest FibroTest SteatoTest Alcohol +3

  312. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 58

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  313. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 58

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  314. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.

    Canbakan M et al. · Nephron Clin Pract · 2011 Match 58

    ### Background Liver biopsy is an imperfect gold standard for assessing the disease…

    FibroTest HCV

  315. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 58

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  316. Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.

    Geri G et al. · J Viral Hepat · 2012 Match 57

    Therapeutic options in hepatitis C virus (HCV)-related vasculitis may target the…

    FibroTest Alcohol HBV HCV +1

  317. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 57

    ### Background The diagnosis of alcoholic liver diseases is based on the history…

    ActiTest AshTest FibroTest NashTest +2

  318. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 57

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  319. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

    Bouayad A et al. · Pan Afr Med J · 2021 Match 57

    ### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…

    ActiTest FibroTest HCV

  320. [SWE elastography in assessment of liver fibrosis].

    Zaleska-Dorobisz U et al. · Postepy Hig Med Dosw (Online) · 2015 Match 57

    Liver fibrosis is a relatively common consequence of chronic liver diseases, especially…

    FibroTest HBV HCV

  321. Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 57

    FibroTest HBV

  322. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.

    Poynard T · Gut · 2003 Match 57

    HCV

  323. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 57

    The aim of this study was to evaluate the diagnostic usefulness of…

    FibroTest Other

  324. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 56

    ### Background Liver fibrosis is a sign of advanced liver disease and is…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  325. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

    Dominguez S et al. · J Antimicrob Chemother · 2010 Match 56

    ### Objectives To compare plasma antiretroviral concentrations in HIV-HCV co-infected and…

    FibroTest HCV HIV

  326. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Match 56

    ### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…

    ActiTest FibroTest HBV

  327. External validation of FibroIndex.

    Halfon P et al. · Hepatology · 2007 Match 56

    FibroTest HCV

  328. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

    Morra R et al. · Hepatology · 2008 Match 56

    FibroTest Alcohol HBV HCV

  329. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 56

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  330. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 56

    ### Background No blood test has been shown to be effective in the…

    FibroTest LCR1 LCR2 Alcohol +3

  331. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

    Terrier B et al. · J Hepatol · 2011 Match 55

    ### Background & Aims Recent findings in hepatitis C virus (HCV)-monoinfected patients have…

    ActiTest FibroTest HCV HIV

  332. Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

    Herman M et al. · Aliment Pharmacol Ther · 2017 Match 55

    FibroTest HCV

  333. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.

    Gangadharan B et al. · PLoS One · 2012 Match 55

    ### Background Liver biopsy is the reference standard for assessing liver fibrosis and…

    FibroTest HCV

  334. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 55

    FibroTest Other

  335. Poynard T, Ratziu V, Imbert-Bismut F, Munteanu M

    Match 55

    ActiTest FibroTest HCV

  336. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.

    Poynard T et al. · J Viral Hepat · 2008 Match 55

    FibroTest HCV

  337. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.

    Elalfy MS et al. · Ann Hepatol · 2013 Match 55

    ### Background The main causes of liver fibrosis in transfusion-dependent thalassemia major…

    ActiTest FibroTest HCV

  338. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.

    Xu XY et al. · PLoS One · 2014 Match 54

    Noninvasive biomarkers have been developed to predict hepatitis B virus (HBV)-related…

    FibroTest HBV

  339. Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di Martino V, Thabut D, Moussalli J, Benhamou Y

    Match 54

    ActiTest FibroTest HCV

  340. Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.

    Schleiger A et al. · Pediatr Cardiol · 2020 Match 54

    Fontan-palliated patients are at risk for the development of Fontan-associated…

    FibroTest Other

  341. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

    Poynard T et al. · Ann Intern Med · 2013 Match 54

    FibroTest HCV

  342. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011 Match 54

    FibroTest HBV HCV HIV

  343. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 54

    ### Aim This study was undertaken to evaluate the hepatic effects of silybum…

    SteatoTest Metabolic

  344. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 54

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest COVID

  345. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 54

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  346. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review

    Surial B et al. · Liver Int · 2021 Match 53

    ### Background & Aims Chronic hepatitis B virus (HBV) infection accounts for 30%-50…

    FibroTest HBV

  347. [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

    Piton A et al. · Ann Biol Clin (Paris) · 2005 Match 53

    ### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…

    ActiTest FibroTest

  348. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 53

    ### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…

    FibroTest SteatoTest HBV HCV +1

  349. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 53

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  350. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 53

    ### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…

    FibroTest Metabolic

  351. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 53

    ### Background Studies have demonstrated that coronary artery calcification on one hand and…

    ActiTest FibroTest NashTest SteatoTest +1

  352. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 53

    ### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…

    ActiTest FibroTest NashTest SteatoTest +1

  353. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.

    Varaut A et al. · Transplantation · 2005 Match 52

    ### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…

    FibroTest HCV

  354. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 52

    ### Aims To evaluate the application of the recently proposed recommendations by the…

    FibroTest NashTest Metabolic

  355. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 52

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver…

    FibroTest HCV

  356. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 52

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest COVID

  357. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores.

    Férard G et al. · Clin Chem Lab Med · 2006 Match 52

    Two multi-component scores (Fibrotest and Actitest) have been proposed to evaluate…

    ActiTest FibroTest HBV HCV

  358. Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant.

    Bignulin S et al. · Ann Hepatol · 2016 Match 52

    ### Unlabelled Background and rationale. Acoustic radiation force impulse (ARFI) is a non…

    FibroTest HCV

  359. Ministère des Affaires Sociales et de la Santé Key publication

    Match 52

    FibroTest HBV HCV

  360. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 51

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest

  361. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 51

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…

    NashTest SteatoTest Metabolic

  362. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.

    Fierbinteanu-Braticevici C et al. · World J Gastroenterol · 2009 Match 51

    ### Aim To investigate the diagnostic accuracy of acoustic radiation force impulse (ARFI…

    FibroTest HCV

  363. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Match 51

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  364. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.

    Schmid P et al. · PLoS One · 2015 Match 51

    ### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…

    FibroTest HCV HIV

  365. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 51

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  366. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 51

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

Showing the full result list. The page is server-rendered and not paginated.